TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22992965

Group type: EXPERIMENTAL
Intervention: Galanthamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 45
Study: 20488908

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 202
Study: 18068442

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic radical nephrectomy (HALN)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Laparoscopic radical nephrectomy (LRN)
Number of subjects: 21
Study: 16164475

Group type: EXPERIMENTAL
Intervention: Acupressure therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Massage treatment and handholding (Control)
Number of subjects: 52
Study: 12098616

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg/kg followed by 4 microg/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of morphine and ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 12
Study: 10398973

Group type: EXPERIMENTAL
Intervention: LumenHance (manganese chloride-based oral contrast agent)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 8833187

Group type: COMPARATOR
Intervention: Sea Level (SL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Canberra (CB)
Number of subjects: 14
Study: 1702939

Group type: EXPERIMENTAL
Intervention: Enteral nutrition administered by needle‐catheter jejunostomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Parenteral nutrition administered by total parenteral nutrition
Number of subjects: 12
Study: 6343656

Group type: COMPARATOR
Intervention: Normal-sodium diet
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 476
Study: 31322833

Group type: EXPERIMENTAL
Intervention: Surgical splenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsurgical (control)
Number of subjects: 0
Study: 30693888

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound and jaw opening exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Jaw opening exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 20
Study: 26227112

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC) intervention delivered by a Health Coach
Number of subjects: 261

Group type: COMPARATOR
Intervention: Education Alone (EA) group
Number of subjects: 261
Study: 23740226

Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab 50 mg monthly for 6 months
Number of subjects: 3366

Group type: COMPARATOR
Intervention: Intravenous plus subcutaneous golimumab
Number of subjects: 3366

Group type: COMPARATOR
Intervention: Subcutaneous golimumab
Number of subjects: 3366
Study: 22852834

Group type: EXPERIMENTAL
Intervention: Nurse-administered Tobacco Tactics intervention
Number of subjects: 6

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6
Study: 20823391

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including pill counting, family support, and educational information.
Number of subjects: 877

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention.
Number of subjects: 877
Study: 18634504

Group type: EXPERIMENTAL
Intervention: YU BHK Rabivak vaccine candidate
Number of subjects: 164

Group type: COMPARATOR
Intervention: Rabipur (commercially available vaccine)
Number of subjects: 164
Study: 15805799

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E and vitamin C supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin and coenzyme Q
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other combinations of antioxidant therapies
Number of subjects: 0
Study: 12394560

Group type: EXPERIMENTAL
Intervention: Energy Conservation and Activity Management (ECAM) intervention, 3 telephone sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care for cancer treatment-related fatigue
Number of subjects: 0
Study: 10426707

Group type: EXPERIMENTAL
Intervention: High energy density, low viscosity (HD-LV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low energy density, low viscosity (LD-LV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High energy density, high viscosity (HD-HV)
Number of subjects: 0
Study: 7562086

Group type: EXPERIMENTAL
Intervention: Feeding status (fed state) with 13C-labeled algae (Spirulina platensis)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fasting (fasted state)
Number of subjects: 4
Study: 2188451

Group type: EXPERIMENTAL
Intervention: Stapler instrument for hysterotomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard technique (control)
Number of subjects: 100
Study: 369348

Group type: EXPERIMENTAL
Intervention: Right heart catheterization via antecubital venous cutdown procedure
Number of subjects: 57

Group type: COMPARATOR
Intervention: Right heart catheterization via percutaneous femoral vein approach
Number of subjects: 57
Study: 30782955

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate aqueous
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol
Number of subjects: 100
Study: 27612588

Group type: EXPERIMENTAL
Intervention: Doula support
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 70
Study: 26484700

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 25509922

Group type: EXPERIMENTAL
Intervention: Gepatomax Forte in conjunction with basal therapy for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal therapy only for 4 weeks
Number of subjects: 0
Study: 22231536

Group type: EXPERIMENTAL
Intervention: Mild hypothermic CPB (32 °C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normothermic CPB (37 °C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between mild hypothermic and normothermic CPB
Number of subjects: 60
Study: 20667604

Group type: EXPERIMENTAL
Intervention: Carboplatin chemotherapy (3-4 courses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carboplatin chemotherapy (higher doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline measurement (before chemotherapy)
Number of subjects: 10
Study: 17227394

Group type: EXPERIMENTAL
Intervention: Interactive MobiTed system
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional multiple choice test
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Native speaking students
Number of subjects: 57
Study: 15110130

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 253
Study: 11260540

Group type: EXPERIMENTAL
Intervention: Cyclosporine (Neoral) treatment until clearance or for a maximum of 12 weeks, followed by randomization into two groups: Group A (stop abruptly) and Group B (taper dose by 1 mg/kg per day until cessation within 4 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cyclosporine (Neoral) treatment
Number of subjects: 76
Study: 9652881

Group type: EXPERIMENTAL
Intervention: Low-dose nitroglycerin patches (5 mg/24 h each)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8093138

Group type: EXPERIMENTAL
Intervention: Cranberry beverage (300 mL per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control (synthetic placebo drink)
Number of subjects: 153
Study: 3147901

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (100 ng kg‐1 h‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (400 ng kg‐1 h‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin infusion
Number of subjects: 6
Study: 29260471

Group type: EXPERIMENTAL
Intervention: EPPM-based mobile phone text message intervention for 2 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 27541044

Group type: EXPERIMENTAL
Intervention: Three true sessions of 10 Hz rTMS
Number of subjects: 98

Group type: COMPARATOR
Intervention: One true and two sham rTMS sessions
Number of subjects: 98
Study: 24132705

Group type: EXPERIMENTAL
Intervention: Compound Amlodipine Tablets with high-fat breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Compound Amlodipine Tablets with overnight fast
Number of subjects: 12
Study: 23531328

Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil (1060 mg EPA plus 274 mg DHA)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (900 mg DHA plus 180 mg EPA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Soy oil placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: EPA-rich fish oil
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Serum DHA concentrations at 34‐36 weeks
Number of subjects: 126
Study: 20193646

Group type: COMPARATOR
Intervention: Continuation pharmacologic intervention (C-PHARM) with nortriptyline plus lithium for 24 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Continuation electroconvulsive therapy (C-ECT) with 10 treatments
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 19013293

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T(3)) at doses of 50 to 75 microg/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T(3))
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T(3)) and Placebo
Number of subjects: 14
Study: 16188778

Group type: EXPERIMENTAL
Intervention: Breastfeeding counselling by lay counsellors during home visits on days 5, 15, 30, 60, 90, and 120 after birth
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Breastfeeding counselling by lay counsellors
Number of subjects: 1003
Study: 12618690

Group type: EXPERIMENTAL
Intervention: Subfascial endoscopic perforating vein surgery (SEPS)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Saphenous vein ligation and stripping
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: SEPS
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Repeat SEPS
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Deep valve repair
Number of subjects: 832

Group type: COMPARATOR
Intervention: Complications
Number of subjects: 832
Study: 10587038

Group type: EXPERIMENTAL
Intervention: Fenretinide for the prevention of contralateral breast cancer
Number of subjects: 1815

Group type: COMPARATOR
Intervention: Retrospective recruitment strategy
Number of subjects: 1815

Group type: COMPARATOR
Intervention: Prospective recruitment strategy
Number of subjects: 1815
Study: 8921055

Group type: EXPERIMENTAL
Intervention: Highly purified human follicle‐stimulating hormone (FSH‐HP), administered s.c. (n = 19)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG), administered i.m. (n = 20)
Number of subjects: 41
Study: 1884733

Group type: EXPERIMENTAL
Intervention: Dipyrone 1 g
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Dipyrone 2 g
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 451
Study: 6412384

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30913305

Group type: EXPERIMENTAL
Intervention: Standard fractionation radiotherapy concurrent with cisplatin (RTOG-0129)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy concurrent with cisplatin (RTOG-0522)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Cisplatin and accelerated fractionation with or without cetuximab (RTOG-0522)
Number of subjects: 547
Study: 30217172

Group type: EXPERIMENTAL
Intervention: IFN β‐1a 22 μg
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: IFN β‐1a 44 μg
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study: 27142721

Group type: EXPERIMENTAL
Intervention: Cognitive Rehearsal (CR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physical Rehearsal (PR)
Number of subjects: 10
Study: 24979287

Group type: EXPERIMENTAL
Intervention: Dyad practice
Number of subjects: 84

Group type: COMPARATOR
Intervention: Individual practice
Number of subjects: 84
Study: 22441345

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 822

Group type: COMPARATOR
Intervention: Telmisartan 40 mg
Number of subjects: 822
Study: 20656351

Group type: EXPERIMENTAL
Intervention: Intravitreal injections for CNV
Number of subjects: 24
Study: 17301739

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 12
Study: 15231557

Group type: EXPERIMENTAL
Intervention: Intramuscular lorazepam (4 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intramuscular haloperidol (10 mg) plus promethazine (25-50 mg mix)
Number of subjects: 200
Study: 11438315

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: CEE 0.45 mg/day
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: CEE 0.625/MPA 2.5 mg/day
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: CEE 0.45/MPA 2.5 mg/day
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: CEE 0.45/MPA 1.5 mg/day
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/day
Number of subjects: 2673

Group type: EXPERIMENTAL
Intervention: CEE 0.3/MPA 1.5 mg/day
Number of subjects: 2673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2673
Study: 9849704

Group type: COMPARATOR
Intervention: Normal pregnancy (control group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pre-eclamptic state
Number of subjects: 18
Study: 7973211

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2570283

Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 7
Study: 164128

Group type: EXPERIMENTAL
Intervention: Brief hospitalization (one week or less) with transitional day care available
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Brief hospitalization without day care
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard inpatient care (discharge at the therapist's discretion)
Number of subjects: 175
Study: 30249694

Group type: EXPERIMENTAL
Intervention: Gepotidacin
Number of subjects: 69
Study: 27833860

Group type: EXPERIMENTAL
Intervention: Lignocaine (2%) with adrenaline (1:100,000)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lignocaine (2%) injection with topical adrenaline (1:10,000)
Number of subjects: 0
Study: 24730575

Group type: EXPERIMENTAL
Intervention: FACTSHEETS - a series of four electronic factsheets
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: HPE - an online interactive health promotion website
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: HPE + MI - the online health promotion website plus two 30-minute calls with a trained motivational interviewer
Number of subjects: 222
Study: 23228097

Group type: COMPARATOR
Intervention: HALDN
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TPLDN
Number of subjects: 100
Study: 19952841

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program (decrease caloric intake and increase physical activity levels)
Number of subjects: 170
Study: 18647281

Group type: EXPERIMENTAL
Intervention: High level of environmental music
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual level of environmental music
Number of subjects: 40
Study: 15610370

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution (single dose)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution (multiple doses)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution (single and multiple doses)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Vehicle placebo (single dose)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Vehicle placebo (multiple doses)
Number of subjects: 133
Study: 11581550

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/d for first 5 days, then 5 g/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (sodium phosphate monohydrate)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 25
Study: 9831573

Group type: EXPERIMENTAL
Intervention: Nutrient enriched preterm formula as sole diet
Number of subjects: 424

Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 424
Study: 7815378

Group type: EXPERIMENTAL
Intervention: Cognitive induction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Behavioral induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 2803681

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4393372

Group type: EXPERIMENTAL
Intervention: Methysergide 3-6 mg daily
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: BC105
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Methdilazine
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Methylergol carbamide maleate
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 31945659

Group type: EXPERIMENTAL
Intervention: Infiltration anaesthesia (IA) with 0.2% ropivacaine (RPV) and FNT 50 μg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Infiltration anaesthesia (IA) with 0.2% bupivacaine (BPV) and FNT 50 μg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 94
Study: 30907141

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 0
Study: 28493877

Group type: EXPERIMENTAL
Intervention: AnapnoGuard™ 100 system (AG)
Number of subjects: 60
Study: 25711974

Group type: EXPERIMENTAL
Intervention: Automated, telephone‐based, interactive voice response (IVR) intervention, called twice weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Automated, telephone‐based, interactive voice response (IVR) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 60
Study: 24238317

Group type: EXPERIMENTAL
Intervention: Point-of-care serum ketone measurement (beta-hydroxybutyrate)
Number of subjects: 188
Study: 21485398

Group type: EXPERIMENTAL
Intervention: promethazine + dexamphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: scopolamine + dexamphetamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: non-immersion control with no drug
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: meclizine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: dimenhydrinate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: chlorpheniramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: promethazine + caffeine
Number of subjects: 12
Study: 19751000

Group type: EXPERIMENTAL
Intervention: Nonmodular components
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All-polyethylene step-cut implants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Metal-backed nonmodular fixed-bearing implants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Modular fixed-bearing implants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fracture
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nonmodular all-polyethylene step-cut devices
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Failure modes
Number of subjects: 50
Study: 16981140

Group type: EXPERIMENTAL
Intervention: HRT with conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: CEE plus MPA
Number of subjects: 526

Group type: COMPARATOR
Intervention: Transdermal estradiol plus MPA
Number of subjects: 526

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 526
Study: 15287931

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily plus a mildly reduced-calorie diet
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study: 11389505

Group type: EXPERIMENTAL
Intervention: Cloxacillin plus gentamicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopeptide (vancomycin or teicoplanin) plus gentamicin
Number of subjects: 0
Study: 9430132

Group type: EXPERIMENTAL
Intervention: Occupational exposure to organic solvents
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (referents)
Number of subjects: 320
Study: 8215644

Group type: EXPERIMENTAL
Intervention: Urokinase 125,000 U
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Urokinase 250,000 U
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Urokinase 500,000 U
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 134
Study: 3684128

Group type: EXPERIMENTAL
Intervention: Bladder training (N = 44)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nonbladder training (N = 45)
Number of subjects: 89
Study: 28601957

Group type: COMPARATOR
Intervention: Coping skills intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Peer helping + coping skills intervention
Number of subjects: 50